A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

Inclusion Criteria:

- Adult participants, >/= 18 years of age

- Participants with multiple basal cell carcinomas, including participants with Gorlin
syndrome, with at least 6 clinically evident basal cell carcinomas at the time of
randomization, of which 3 measure 5 mm or more in diameter and are considered target
lesions. All other lesions are considered to be non-target lesions

- Histopathologic confirmation that at least one of the three target lesions is basal
cell carcinoma

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

- Adequate renal and hepatic function and hematopoietic capacity

- Women of childbearing potential must agree to use contraception as defined by protocol
during treatment and for at least 9 months after completion of study treatment

- Male participants with female partners of childbearing potential must agree to use
contraception as defined by protocol during treatment and for 2 months after
completion of study treatment

Exclusion Criteria:

- Inability or unwillingness to swallow capsules

- Pregnant or breastfeeding women

- Any metastatic basal cell carcinoma

- Locally advanced basal cell carcinoma lesion that is considered to be inoperable or to
have medical contraindications to surgery

- Recent (i.e., within the past 28 days prior to randomization) or current participation
in another experimental drug study

- Known or suspected alcohol abuse

- One of the following known rare hereditary conditions: galactose intolerance, primary
hypolactasia or glucose-galactose malabsorption